GHRP-6

Research-Documented Benefits

• Potent GH Secretion — GHRP-6 is one of the strongest growth hormone releasing peptides, producing robust, dose-dependent GH pulses via ghrelin receptor activation.
• Appetite Stimulation — As a ghrelin mimetic, GHRP-6 stimulates appetite through hypothalamic signaling, which may support research in cachexia and wasting conditions.
• Cytoprotective Effects — Research demonstrates cardioprotective and hepatoprotective properties, with reduced ischemia-reperfusion injury in animal models.
• IGF-1 Increase — Sustained administration elevates IGF-1 levels, supporting downstream anabolic and tissue repair pathways.
• Anti-Fibrotic Properties — Studies indicate reduced fibrosis in liver and cardiac tissue models, suggesting anti-scarring potential.

Mechanism of Action

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a hexapeptide that mimics the endogenous hormone ghrelin, activating the growth hormone secretagogue receptor type 1a (GHS-R1a).

Primary Pathways

• Ghrelin Receptor Activation — GHRP-6 binds GHS-R1a with high affinity, triggering intracellular calcium mobilization and protein kinase C activation in pituitary somatotrophs.
• Dual GH Release — Promotes GH secretion through both direct pituitary stimulation and hypothalamic GHRH release, while simultaneously suppressing somatostatin, producing robust GH pulses.
• Appetite Stimulation — Activates hypothalamic NPY/AgRP neurons via GHS-R1a, mimicking ghrelin's orexigenic signaling and increasing food intake.
• Cytoprotective Signaling — Activates PI3K/Akt survival pathways in cardiac and hepatic cells, providing protection against ischemia-reperfusion injury.

GHRP-6's broad receptor activation—including appetite stimulation and cortisol release alongside potent GH secretion—distinguishes it from more selective secretagogues like ipamorelin.

Research Protocol Guidelines

All protocols described are for in vitro and in vivo research purposes only. Not for human use.

Reconstitution

Reconstitute lyophilized GHRP-6 with bacteriostatic water. For a 5 mg vial, adding 2.5 mL yields 2 mg/mL.

Research Dosing (Preclinical Literature)

• GH stimulation: 1-2 mcg/kg subcutaneously or intravenously in rodent GH-axis studies
• Appetite studies: 100-300 mcg/kg IP in feeding behavior research models
• Cardioprotection: 100 mcg/kg IP prior to induced ischemia in cardiac research models
• Timing: Administered on an empty stomach in metabolic studies; appetite stimulation onset within 20-30 minutes

Storage

Store lyophilized form at -20°C. Reconstituted at 2-8°C, use within 21 days. GHRP-6 is stable in lyophilized form for up to 24 months at proper storage temperature.

Safety & Handling Information

For research use only. Not intended for human or veterinary diagnostic or therapeutic use.

Storage Requirements

• Lyophilized: -20°C, desiccated
• Reconstituted: 2-8°C, use within 21 days

Preclinical Safety Profile

GHRP-6 has been extensively studied since its synthesis in the 1980s. It is well-tolerated in preclinical models, though its broad receptor activation produces more side effects than selective secretagogues.

Known Considerations

• Appetite stimulation (ghrelin-mimetic effect) may confound metabolic or feeding behavior studies
• Transient cortisol and prolactin elevations at higher doses may affect endocrine-focused research
• Gastric acid secretion increase may be relevant in GI research models
• Standard GH/IGF-1 axis neoplasia considerations apply

Handling

Standard laboratory PPE. GHRP-6 is chemically stable and straightforward to handle under standard peptide protocols.

Frequently Asked Questions